European Commission approves Kyprolis for combination use in patients with relapsed multiple myeloma

Amgen has announced the European Commission (EC) granted marketing authorization for Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult… Source link